Blood Glucose Test — Test Guide & Results Explained — Purpose, Procedure & Normal Values | MyMedicPlus

A blood glucose test measures the concentration of glucose — the body's primary energy substrate — circulating in the bloodstream at the time of sampling. Glucose enters the blood from dietary carbohydrates and is regulated by insulin secreted from pancreatic beta cells; impaired insulin action or secretion leads to elevated blood glucose (hyperglycaemia), the hallmark of diabetes mellitus. Testing forms include fasting plasma glucose (FPG), measured after at least 8–12 hours without caloric intake; random plasma glucose, obtained at any time; the oral glucose tolerance test (OGTT), which challenges the body with a standardised 75 g glucose load and measures the 2-hour response; and glycated haemoglobin (HbA1c), a surrogate marker reflecting the average blood glucose over the preceding 2–3 months. These tests are ordered by general practitioners, endocrinologists, obstetricians, and used in routine preventive health screening programmes worldwide. Together, they diagnose, classify, and monitor all forms of diabetes mellitus and guide treatment intensification.

Blood glucose testing is ordered to screen for and diagnose Type 1 diabetes (autoimmune beta-cell destruction, often presenting acutely in younger patients), Type 2 diabetes (progressive insulin resistance and secretory failure, often asymptomatic for years), prediabetes (impaired fasting glucose or impaired glucose tolerance), and gestational diabetes mellitus (GDM), which is routinely tested at 24–28 weeks of pregnancy using a 75 g OGTT or a two-step challenge. It investigates symptoms of hyperglycaemia — polydipsia (excessive thirst), polyuria (frequent urination), unexplained weight loss, blurred vision, fatigue, and recurrent infections — as well as symptoms of hypoglycaemia including trembling, sweating, palpitations, and confusion. Monitoring tests track glycaemic control in known diabetics and guide adjustment of insulin or oral hypoglycaemic agents. The test is also part of pre-operative assessment, metabolic syndrome evaluation, and medication safety monitoring in patients taking corticosteroids or atypical antipsychotics.

For a fasting plasma glucose test, avoid all food, milk, juice, and caloric beverages for 8–12 hours before the blood draw; plain water is encouraged and permitted. Do not alter your diabetes medications without your doctor's specific guidance — most oral agents and insulin doses should be taken as usual unless instructed otherwise. Avoid strenuous aerobic exercise immediately before the test, as physical activity can lower blood glucose and cause a falsely reassuring fasting result. For a random glucose test, no preparation is required. For an OGTT, fast for 8 hours, arrive at the laboratory, have a baseline blood draw, then consume a standardised 75 g anhydrous glucose solution within 5 minutes; a second blood sample is drawn exactly 2 hours later. For an HbA1c test, no fasting or preparation is needed. Inform your doctor of any recent acute illness or infection, which can temporarily raise blood glucose and affect interpretation.

A phlebotomist cleans the antecubital fossa (inner elbow) with an antiseptic swab and applies a tourniquet to raise the vein. A sterile needle is inserted into the cubital vein and 2–4 mL of blood is collected into a grey-top fluoride oxalate tube, which inhibits cellular glucose metabolism and preserves the sample accurately during transport to the laboratory. The process takes 3–5 minutes with only brief, minor needle discomfort. For a bedside point-of-care test, the technician pricks the fingertip with a lancet, places a small blood droplet on a glucose test strip, and inserts it into an electronic glucometer for a result within 5–10 seconds. Point-of-care glucometers provide immediate results but are slightly less precise (±15% variation) than laboratory plasma analysers. The laboratory result, available within 1–4 hours, is the reference standard for diagnosis.

Fasting plasma glucose (FPG): Normal <100 mg/dL (<5.6 mmol/L); Prediabetes (impaired fasting glucose) 100–125 mg/dL (5.6–6.9 mmol/L); Diabetes mellitus ≥126 mg/dL (7.0 mmol/L) — requires confirmation on a second day unless the patient is symptomatic. Random plasma glucose: ≥200 mg/dL (11.1 mmol/L) with classic diabetes symptoms confirms diabetes. OGTT 2-hour glucose: Normal <140 mg/dL (<7.8 mmol/L); Impaired glucose tolerance (prediabetes) 140–199 mg/dL (7.8–11.0 mmol/L); Diabetes ≥200 mg/dL (11.1 mmol/L). HbA1c: Normal <5.7% (<39 mmol/mol); Prediabetes 5.7–6.4% (39–47 mmol/mol); Diabetes ≥6.5% (≥48 mmol/mol). Hypoglycaemia is defined as blood glucose below 70 mg/dL (3.9 mmol/L); clinically significant hypoglycaemia below 54 mg/dL (3.0 mmol/L). Low glucose is addressed with fast-acting carbohydrates. Results must be corroborated with clinical presentation and repeated on a separate day before a diagnosis of diabetes is established.

Blood glucose testing is extremely safe. Minor bruising, soreness, or small haematoma at the venepuncture site are the most common side effects, occurring in fewer than 5% of blood draws. Point-of-care glucometer readings can deviate from laboratory values by up to 15%, are affected by altitude, dehydration, severe anaemia (very high haematocrit), or dirty fingertips, and are not suitable for diagnostic purposes. Multiple medications cause clinically significant glucose elevation: corticosteroids (prednisolone, dexamethasone), thiazide diuretics, beta-blockers, atypical antipsychotics (olanzapine, clozapine), and immunosuppressants. Acute illness, severe physical stress, and surgery can transiently push glucose into the diabetic range without true underlying diabetes — a diagnosis should not be made during acute hospitalisation unless two separate confirmatory values are obtained. HbA1c is unreliable in conditions that shorten red blood cell lifespan — haemolytic anaemia, iron deficiency anaemia, sickle cell disease, thalassaemia, G6PD deficiency — where it may falsely underestimate or overestimate average glucose. Cystatin C-based alternatives or continuous glucose monitoring may be more informative in these cases.